For the quarter ending 2025-09-30, IKT had -$39,472,963 decrease in cash & cash equivalents over the period. -$10,592,730 in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -11,930,280 | -23,594,258 |
| Depreciation | 23,687 | 36,812 |
| Stock-based compensation expense | 4,525,206 | 6,250,938 |
| Write-off of in-process research and development | 0 | 7,357,294 |
| Change in fair value contingent consideration | 492,827 | 1,523,284 |
| Noncash accretion on marketable securities | 570,503 | - |
| Operating lease right-of-use assets | 34,918 | 66,519 |
| Prepaid expenses and other assets | -249,795 | -7,526 |
| Prepaid research and development | 1,071,711 | 57,547 |
| Other assets | 57,913 | - |
| Accounts payable | -1,983,355 | 1,592,656 |
| Operating lease liabilities | 37,944 | 72,573 |
| Accrued expenses and other current liabilities | 718,197 | 258,156 |
| Net cash used in operating activities | -10,592,730 | -9,677,761 |
| Purchases of equipment and improvements | 0 | 13,399 |
| Purchases of investments - marketable securities | 38,996,000 | 0 |
| Maturities of investments - marketable securities | 10,249,897 | 31,350,103 |
| Acquired in-process research and development | 0 | 438,624 |
| Net cash provided by investing activities | -28,746,103 | 30,898,080 |
| Deferred offering costs | -385,062 | - |
| Proceeds from issuance of common stock, pre-funded warrants and warrants, net of issuance costs | 0 | 150 |
| Issuance of common stock from exercise of stock options | 250,932 | 31,621 |
| Net cash provided by (used in) financing activities | -134,130 | 31,771 |
| Net decrease in cash and cash equivalents | -39,472,963 | 21,252,090 |
| Cash and cash equivalents at beginning of period | 56,490,579 | - |
| Cash and cash equivalents at end of period | 38,269,706 | - |
Inhibikase Therapeutics, Inc. (IKT)
Inhibikase Therapeutics, Inc. (IKT)